Development of a peptide as a novel therapy for brochial asthma

• Project/Area Number: 26461565
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: The University of Tokyo
• Principal Investigator: YASUDO HIROKI 東京大学, 医学部附属病院, 助教 (70422285)
• Co-Investigator(Kenkyū-buntansha): 磯島 豪 帝京大学, 医学部, 講師 (00568230) ; 三牧 正和 帝京大学, 医学部, 教授 (40392419) ; 加藤 元博 国立研究開発法人国立成育医療研究センター, 小児血液・腫瘍研究部, 医長 (40708690)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 気管支喘息 / 治療 / ペプチド / ペプチド療法 / エンドタイプ

Outline of Final Research Achievements

We aim to develop a molecular based drug as a novel therapy for bronchial asthma.
In this study, we have shown that the introduction of Src homology region 2 (SH2) domain-containing phosphatase 1 (SHP-1) with TAT vector (protein carrier) have brought a decrease in the total cell counts and eosinophil counts in bronchoalveolar lavage fluid of asthmatic mice. This result shows this therapy could suppress inflammation in respiratory tracts and could be a novel therapy for the disease.

Research Products

• [Book] 小児科学レクチャー vol.4 No2 子どもの気管支喘息ガイドラインと薬剤を使いこなすプロの診断センス. その他の気管支喘息の増悪因子 (2014)
  • Author(s): 安戸 裕貴
  • Publisher: 総合医学社